Eli Lilly's (LLY) Tirzepatide "Mega-blockbuster Potential" is Confirmed, Morgan Stanley Reiterates Overweight
Tweet Send to a Friend
Morgan Stanley analyst David Risinger reiterated an Overweight rating and $217.00 price target on Eli Lilly (NYSE: LLY) after all ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
